Speciality Medicines IPO opens: Issue booked 15% so far; check GMP, price band and other key details about SME IPO

Speciality Medicines IPO Day 1: Speciality Medicines IPO, worth 29 crore, opened for bidding today and will available till March 24. The offer is entirely a fresh share sale. Speciality Medicines IPO GMP remains nil.

Saloni Goel
Published20 Mar 2026, 11:29 AM IST
Speciality Medicines IPO GMP today is  <span class='webrupee'>₹</span>0. This means that shares of Speciality Medicines are trading at neither a premium nor a discount to the offer price.
Speciality Medicines IPO GMP today is ₹0. This means that shares of Speciality Medicines are trading at neither a premium nor a discount to the offer price.

Speciality Medicines IPO: Pharma company Speciality Medicines launched its initial public offering (IPO) on BSE SME today, March 20. The 29-crore public offering is available for bidding till Tuesday, March 24.

Speciality Medicines IPO is entirely a fresh issue of 0.24 crore shares, with no offer for sale component. This means all proceeds will be received by the company. The IPO is priced in the range of 117 to 124 apiece.

The company plans to use 12.68 crore from the funds raised for setting up an R&D centre, 2.99 crore for product registration and sale in international markets, and 1.66 crore will be spent on marketing and promotional activities. Lastly, 8 crore will be deployed to meet working capital needs and the rest for general corporate purposes.

Also Read | Central Mine Planning IPO Day 1 LIVE: IPO booked 2% so far — Apply or not?

Investors can apply for the IPO in lots of 1000 shares. For retail investors, the minimum application size is 2000 shares, resulting in an investment of 2,48,000 at the upper end of the price band.

Unistone Capital is the book running lead manager to the SME IPO and Skyline Financial Services is the registrar of the issue.

Speciality Medicines IPO subscription

According to BSE data, Speciality Medicines IPO was subscribed 15% as of 11.15 am as it garnered bids for 3,56,000 shares as against 23,50,000 shares on offer. The retail portion was subscribed 2% so far, while the non-institutional investor (NII) quota was subscribed 27%.

Lastly, the qualified institutional buyer (QIB) segment remained unsubscribed.

Speciality Medicines IPO GMP

The grey market premium (GMP) for Speciality Medicines was lacklustre. According to the websites tracking the unofficial market, Speciality Medicines IPO GMP today is 0. This means that shares of Speciality Medicines are trading at neither a premium nor a discount to the offer price.

Also Read | SBI, Amundi to offload 10% in SBI Funds IPO, no fresh shares to be issued

At the prevailing GMP, Speciality Medicines IPO listing price could be the same as the offer price. The GMP signals investor willingness to pay over and above the issue price for an IPO.

Shares of Speciality Medicines are slated to list on the BSE SME platform on March 30.

About the company

Speciality Medicines is engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas such as oncology, immunology, neurology, and rare diseases.

The company operates through two integrated business models: Manufacturing, on a contract manufacturing basis, approved finished formulations and distributing them internationally; and marketing and distribution of specialty pharmaceutical products sourced from manufacturers.

About the Author

Saloni Goel has over nine years of experience as a business journalist, with a strong track record of covering the financial markets. Over the course of her career, she has reported extensively on global and domestic equities, IPO market activity, commodities, and broader macroeconomic trends. Her reporting reflects a keen eye for detail, data-driven analysis, and the ability to spot emerging themes early.<br> At Mint, Saloni has been part of the markets team for nearly two years, where she currently works as Chief Content Producer. In this role, she plays a key part in shaping market coverage, driving editorial strategy, and ensuring timely, accurate, and insightful reporting across. She has been closely involved in breaking news coverage and in crafting stories that help decode the complex financial developments.<br> Before joining Mint, Saloni worked with some of India’s leading business newsrooms, including The Economic Times and Business Standard. Throughout her career, she has worn multiple hats—ranging from reporting and editing to contributing in-depth features and identifying new storytelling formats and market trends.<br> Her experience in fast-paced digital newsrooms has given her an edge in simplifying complex market concepts without losing analytical depth. Outside of work, Saloni enjoys reading books and spending time with her pet.

Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

HomeMarketsIPOSpeciality Medicines IPO opens: Issue booked 15% so far; check GMP, price band and other key details about SME IPO
More